Cenk Sumen is an internationally recognized expert in advanced
therapies. He has served in technical and business management roles
of increasing responsibility for Thermo Fisher Scientific, Hitachi
Chemical Advanced Therapeutics Solutions, PerkinElmer, Stemcell
Technologies, Life Technologies, and Invitrogen, specializing in building
innovation partnerships, advancing process development, and
establishing sustainable manufacturing platforms. Dr. Sumen received
his BS in biology from Massachusetts Institute of Technology, and his
Ph.D. in microbiology and immunology from Leland Stanford Junior
University, and he currently teaches as an Adjunct Professor at New
York University Tandon School of Engineering.